Stage IB Breast Cancer Clinical Trial
Official title:
Multi-institution Phase II Trial of Intraoperative Electron Beam Radiotherapy Boost at the Time of Breast Conserving Surgery With Oncoplastic Reconstruction in Women With Early-Stage Breast Cancer
This phase II trial studies the side effects of intraoperative electron beam radiotherapy boost and to see how well it works in treating patients with stage I-II breast cancer undergoing surgery with reconstruction. Giving a single dose of electron beam radiation to the tumor cavity during the breast surgery before reconstruction may be a better way to kill tumor cells and shrink tumors.
Status | Recruiting |
Enrollment | 176 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Pathologically proven diagnosis of breast cancer - Clinical node negative stage I (T1N0) or stage II (T2N0) breast cancer - Preoperative ultrasound of the axilla with biopsy of suspicious nodes is recommended as clinically indicated per the discretion of the treating physician - Appropriate stage for protocol entry including no clinical evidence for distant metastases based upon the following minimum diagnostic workup - History/physical examination, documentation of weight and Zubrod performance status 0-2 within 28 days prior to study entry - Right and left mammography within 90 days of diagnostic biopsy establishing diagnosis - Absolute neutrophil count > 1800 cells/cubic mm - Platelets >= 75,000 cells/cubic mm - Hemoglobin >= 8 g/dL - Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study entry - Women of childbearing potential must be non-pregnant and non-lactating and willing to use medically acceptable form of contraception during radiation therapy - Patients must provide study specific informed consent prior to study entry Exclusion Criteria: - Clinical T4, N2 or N3, M1 pathologic stages III or IV breast cancer - Prior invasive non-breast malignancy (except non-melanoma skin cancer, carcinoma in situ of the cervix) unless disease free for a minimum of 3 yrs prior to study entry - Prior invasive or in-situ carcinoma of the breast (prior lobular breast carcinoma in situ [LCIS] is eligible) - Two or more cancers not resectable through a single lumpectomy incision - Bilateral breast cancer - Ductal breast carcinoma in situ (DCIS) only - Non-epithelial breast malignancies such as sarcoma/lymphoma - Male breast cancer - Paget's disease of the nipple - Prior radiotherapy to the breast or prior radiation to the region of the ipsilateral breast that would result in overlap of radiation fields - Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception - Active systemic lupus, erythematosus, or any history of scleroderma, dermatomyositis with active rash - Medical, psychiatric or other condition that would prevent the patient from receiving the protocol therapy or providing informed consent |
Country | Name | City | State |
---|---|---|---|
Canada | Centre Hospitalier de I'Universite de Montreal | Québec | Montreal |
United States | University of North Carolina | Chapel Hill | North Carolina |
United States | University Hospitals | Cleveland | Ohio |
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
United States | Avera Cancer Institute | Sioux Falls | South Dakota |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of adverse events in the first 30 patients enrolled as graded by the National Cancer Institute Common Toxicity Criteria version 4.0 | If 4 or more complications in the first 10 patients, 7 or more out of the first 20 patients or 9 or more out of 30 patients are observed, then the study will be deemed not safe to continue. Summary statistics will be used to report all complications. | Up to 30 days after surgery and IOERT boost | |
Primary | Rate of grade 3 fibrosis using the Late Effects Normal Tissue Task Force-Subjective, Objective, Management, Analytic scales | The proportion of patients with an overall response rate of grade 3 fibrosis at 1 year from the end of therapy along with the exact binomial confidence interval for the rate will be calculated. | At 1 year from the end of therapy | |
Secondary | Change in self-reported cosmesis using the BCTOS | The mean and standard deviation of the self-reported cosmesis using the BCTOS cosmesis scale will be summarized over time. The change over time using a repeated measures model or non-parametric methods, if appropriate, will be examined. | Baseline up to 3 years | |
Secondary | Physician reported cosmesis using the Harvard Breast Cosmesis scale and digital photographs | physician-reported cosmetic outcomes using the 4-point Harvard Cosmesis Scale and digital photographs | Up to 3 years after completion of radiation therapy | |
Secondary | Quality of life assessed by Breast Cancer Treatment Outcome Scale | determine the rate of surgical complications necessitating hospital readmission or return to the operating room within 30 days of surgery + IOERT | Up to 3 years after completion of radiation therapy | |
Secondary | Rate of ipsilateral breast tumor recurrence | The exact binomial confidence interval for the rate will be calculated. | At 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02235051 -
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
|
N/A | |
Completed |
NCT03233555 -
Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer
|
N/A | |
Terminated |
NCT02454777 -
High-Intensity Interval Training for Stage I-III Breast Cancer Patients
|
N/A | |
Completed |
NCT03061175 -
Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy
|
N/A | |
Recruiting |
NCT03156309 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Completed |
NCT01928186 -
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
|
N/A | |
Terminated |
NCT01222377 -
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
N/A | |
Active, not recruiting |
NCT02780401 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Terminated |
NCT01409811 -
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
|
N/A | |
Completed |
NCT02728596 -
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
|
N/A | |
Completed |
NCT01478477 -
Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole
|
N/A | |
Completed |
NCT02314156 -
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
|
Phase 2 | |
Completed |
NCT01672684 -
Phase I: At-Home Support for Rural Women Using Group Video Calling
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00194779 -
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT02566408 -
Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity
|
N/A | |
Terminated |
NCT02370264 -
Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer
|
N/A | |
Terminated |
NCT01243541 -
Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel
|
N/A | |
Completed |
NCT01941784 -
Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy
|
N/A | |
Terminated |
NCT01712815 -
PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer
|
N/A |